Monday, June 19, 2017

Vital Art and Science Inks License With Genentech

Dallas-based Vital Art and Science says this morning that it has signed a licensing agreement with Genentech, which will allow Genentech to use its mVT App service in Genentech's studies. Financial details of the deal were not announced. Vital Art and Science said is app is currently being used in a study by Genentech in its Phase II LADDER study (NCT02510794) for patients with wet age-related macular degeneration (AMD). Vital Art and Science's mVT app lets users track their vision on their iOS or Android phone, helping to detect if a patient's vision is worsening or improving.